Status:
COMPLETED
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Malignant Glioma
Eligibility:
All Genders
Brief Summary
Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- All-patient of Gliadel implantation
- Exclusion criteria:
- None
Exclusion
Key Trial Info
Start Date :
January 10 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 24 2015
Estimated Enrollment :
561 Patients enrolled
Trial Details
Trial ID
NCT02300532
Start Date
January 10 2013
End Date
March 24 2015
Last Update
February 27 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka, Osaka, Japan
2
Tokyo, Tokyo, Japan